Amgen To Present At The Oppenheimer Global Health Care Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
While Amgen (AMGN) Primary Endpoint Was Below Expectations, Secondary Endpoint was Encouraging - Goldman Sachs
March 17, 2017 11:05 AM EDTGoldman Sachs analyst Terence Flynn weighed in on Amgen (NASDAQ: AMGN) after full data from Repatha (PCSK9) Ph3 cardiovascular outcomes trial, FOURIER, was presented.
Flynn commented, "In our view the primary endpoint effect is likely below investor expectations (hence why AMGN... More
